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Purpose: Heterozygous mutations in the myocilin gene (MYOC) cause glaucoma by an unknown mechanism. MYOC
encodes an extracellular protein of unidentified function that undergoes intracellular endoproteolytic processing in the
secretory pathway. It has been described that co-expression of wild-type/mutant myocilin reduces the secretion of the
wild-type protein and that single expression of glaucoma myocilin mutants reduces its proteolytic processing. However,
the effect of wild-type myocilin on mutant myocilin secretion and how mutant myocilin affects the proteolytic processing
of wild-type myocilin have not been investigated. We herein analyze these two issues.
Methods: We modeled the heterozygous state for 4 missense (E323K, R346T, P370L, D380A) and 1 nonsense (Q368X)
myocilin mutants by transiently co-expressing each mutant with the wild-type protein in HEK-293T cells. Recombinant
mutant and wild-type myocilin in both culture media and cellular fractions were quantified by western immunoblot and
densitometry.
Results: A 24 h transient co-expression of each myocilin mutant with the wild-type protein elicited an augmented secretion
of the mutant forms from 1.5 fold (D380A) to 5.4 fold (E323K). Under such conditions, extracellular mutant myocilin
represented up to 20% of the total mutant protein. Other than this effect, secreted wild-type myocilin significantly
decreased from 2.6 fold (E323K) to 36 fold (Q368X). When myocilin proteolytic processing was enhanced (96 hour co-
expression) the extracellular amount of wild-type processed myocilin diminished from approximately 2.1 fold (E323K)
to 6.3 fold (P370L). Nonreducing SDS-PAGE indicated that extracellular myocilin resulting from 24 h co-expression of
wild-type myocilin and each of the 4 missense mutants forms hetero-oligomers and that glaucoma mutations do not
increase the size of myocilin aggregates.
Conclusions: Increased extracellular levels of mutant myocilin expressed in heterozygosis may play a relevant role in
glaucoma pathogenesis. This effect is likely the result of intracellular mutant/wild-type myocilin hetero-oligomerization.
Glaucoma  encompasses  a  heterogeneous  group  of
neurodegenerative  diseases  as  a  result  of  the  progressive
degeneration  of  the  optic  nerve  and  loss  of  visual  fields.
Primary open-angle glaucoma (POAG; OMIM 137760) is the
most frequent type of glaucoma. This disease is the second
leading cause of bilateral blindness in developed countries.
Indeed, it is estimated that 3-5% of the world population over
40 years of age will develop glaucoma [1], affecting some 60
million people by the year 2010 [2]. Elevated intraocular
pressure (IOP) is the main known risk factor of this disease.
In most POAG patients increased resistance to the outflow of
aqueous humor (AH) in the trabecular meshwork (TM) results
in an increment of IOP, causing ganglion cell death in the
neural retina [3,4], and subsequent progressive visual loss.
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MYOCILIN  (MYOC;  OMIM  601652)  was  the  first  gene
identified in glaucoma [5]. Mutations in this gene are mainly
confined  to  exon  3,  which  encodes  the  olfactomedin-like
domain of the protein [6-8]. Heterozygous MYOC mutations
segregate  with  the  disease  in  a  subset  of  families  with
autosomal dominant juvenile-onset, and are present in 3-5%
of patients with adult-onset POAG. MYOC encodes a 55-57
kDa extracellular glycoprotein of an unknown function that
forms  homo-oligomers  of  more  than  116  kDa  [9-11].
Myocilin  shows  a  modular  structure  consisting  of  three
domains: 1) the NH2-terminal leucine zipper-like region; 2) a
central putative linker domain; and 3) the COOH-terminal
olfactomedin-like domain. These domains are encoded by
exons  1,  2,  and  3,  respectively.  This  protein  is  relatively
abundant in the ciliary body, iris, retina, TM [12,13], and in
the AH [14]. It is proteolytically cleaved between amino acids
Arg226-Ile227 by calpain II in the lumen of the ER [9,15]. A
COOH-terminal proteolytic fragment resulting from cleavage
between amino acids Glu214-Leu215 has also been reported
Molecular Vision 2008; 14:2097-2108 <http://www.molvis.org/molvis/v14/a246>
Received 1 September 2008 | Accepted 14 November 2008 | Published 21 November 2008
© 2008 Molecular Vision
2097in HEBNA 293 cells [16]. The processed COOH-terminal
domain is secreted into the culture medium, while the NH2-
terminal fragment mainly remains intracellularly retained [9,
15]. It has been suggested that this processing could regulate
the interaction of myocilin with other proteins [15].
The mechanism by which mutant myocilin causes the
glaucoma  phenotype  remains  elusive.  Over  recent  years
however, some hypotheses have been formulated to explain
the pathogenicity of MYOC mutations. Biochemical and cell
biological  studies  have  provided  evidence  of  a  gain-of-
function  disease  model  [17].  MYOC  disease-causing
mutations  produce  misfolded  polypeptides  [18-20]  which
show reduced secretion both in cells in culture [9,19,21] and
in transgenic mice [22-24]. Non-secreted mutant myocilin
could compromise the proteosomal function, leading to cell
death [20,25,26]. In addition, it has been reported that wild-
type/mutant heteromeric aggregates inhibit the secretion of
the wild-type protein in cells in culture [11,19,20]. However,
the effect of wild-type myocilin on secretion of the mutant
protein has not been investigated. Likewise, it has previously
been reported that MYOC mutations reduce the proteolytic
processing of myocilin [9], but whether heterozygosis affects
the proteolytic processing of myocilin has not been analyzed.
In  the  present  study,  we  investigate  the  pathogenic
mechanism by which heterozygous mutations in MYOC cause
glaucoma. We found that co-expression of wild-type and each
of 5 different mutant myocilins, lead to a significant increase
in  the  secretion  of  the  mutant  myocilins,  along  with  a
reduction  of  the  extracellular  wild-type  proteolytically
unprocessed and processed protein, probably by a dominant
negative  mechanism  mediated  by  heteroaggregation.  We
speculate that the extracellular presence of mutant myocilin
could be a key element in the molecular mechanisms that lead
to glaucoma.
METHODS
Myocilin  constructs:  The  cDNAs  encoding  wild-type  and
glaucoma-causing  myocilin  mutants  were  cloned  into  the
EcoRI-BamHI  sites  of  the  pcDNA3.1-myc-His  [9]  and
pcDNA3.1-HA-His mammalian expression vectors, used as
previously described [9].
Cell  transfections:  The  human  embryonic  kidney  293T
(HEK-293T) cell line was bought from the ATCC (American
type  Culture  Collection,  Manassas,  VA),  and  it  was
maintained  in  Dulbecco’s  modified  Eagle’s  medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and antibiotics (Normocin; Invivogen, Tolousse, France) at
37 °C, in a fully humidified 5% CO2 atmosphere. Transient
plasmid transfections were carried out with 400 ng of total
DNA (200 ng of each cDNA construct in co-transfection
assays, and 200 ng of the cDNA construct, plus 200 ng of the
non-recombinant  pcDNA3.1-myc-His  vector  in  single
transfection assays) using the Superfect Transfection Reagent
(Quiagen, Valencia, CA), as described [15]. The efficiency of
transfections was estimated in cells transiently transfected
with a cDNA construct encoding GFP by counting the number
of GFP-positive cells in a total of 103 cells in four randomly
selected areas per dish. The cells were cultured for either 24
or 96 h after transfection to control the degree of myocilin
processing [15].
Western  blotting  and  antibodies:  Analytical  10%
polyacrylamide gel electrophoresis in the presence of SDS
was  performed  using  the  Mini-PROTEAN  III  gel
electrophoresis system (Bio-Rad, Hercules, CA). For western
blot analysis, aliquots of culture medium and cell lysates were
treated  with  loading  buffer  containing  β-mercaptoethanol,
boiled  for  5  min,  and  fractionated  by  SDS-PAGE.  For
nonreducing SDS-PAGE, samples were treated with loading
buffer without β-mercaptoethanol, without boiling, and were
loaded  onto  either  8%  polyacrylamide  gels  or  4-15%
polyacrylamide gradient gels (Ready Gel, Bio-Rad). Samples
were normalized for protein content using the Bradford assay.
Alpha-tubulin was detected by western blot using a mouse
monoclonal alpha-tubulin antibody (Sigma, St Louis, MO)
diluted at 1:5000 as a loading control in cell lysates. Gels were
subsequently  transferred  onto  Hybond  ECL  nitrocellulose
membranes  (Amersham,  Uppsala,  Sweden)  for
immunodetection. Commercial mouse monoclonal anti-myc
and anti-HA antibodies (Santa Cruz, Santa Cruz, CA) were
used as primary antibodies, diluted at 1:500. A horseradish
peroxidase-conjugated antibody against mouse IgG (Pierce
Biotechnology,  Rockford,  IL)  was  diluted  at  1:1000.
Chemiluminiscence was performed with Supersignal Dura
Western Blot reagents (Pierce). Densitometry for protein band
quantitation was performed on scanned films using Quantity
One 4.1 analysis software (BioRad) on triplicated independent
experiments.  The  percentage  of  unprocessed  myocilin  in
either  the  culture  medium  or  the  cellular  fraction  was
calculated as: (extracellular myocilin/total myocilin) x 100 or
(intracellular  myocilin/total  myocilin)  x  100,  respectively.
Total myocilin in each experiment was calculated as the sum
of all the myocilin signals in both the culture medium and the
cellular fraction. Data were statistically treated by SigmaStat
2.0 software (SPSS Science, Chicago, IL).
RESULTS
Analysis  of  mutant  myocilins  co-expressed  with  wild-type
myocilin: Most MYOC mutations identified today in adult-
onset and autosomal dominant juvenile-onset POAG patients
are present in the heterozygous state. To study the mechanism
by which these mutations lead to glaucoma, we have used a
cellular model of heterozygosis. The heterozygous state was
simulated by transiently co-expressing in HEK-293T cells,
wild-type-HA  myocilin,  and  each  of  4  different  missense
(E323K, R346T, P370L, and D380A) or 1 nonsense (Q368X)
mutant myocilins found in glaucoma patients. Mutant proteins
were  tagged  at  their  COOH-terminal  end  with  the  myc-
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2098epitope (Figure 1). Three of the missense mutations were
selected  because  they  were  considered  representative  of
autosomal dominant glaucoma (E323K, P370L, and D380A)
[27-29]. The fourth missense mutation (R346T), identified in
a  Spanish  patient  with  POAG  [30]  was  considered  as  an
example of a myocilin variant involved in non-Mendelian
glaucoma, whereas the nonsense mutation Q368X has been
found in both autosomic dominant juvenile-onset glaucoma
and non-Mendelian cases of glaucoma [5].The HEK-293T
cell line was chosen because is well characterized, allows easy
expression of recombinant proteins and has been previously
used as a cellular model to study different recombinant human
proteins including myocilin [9,25,31,32]. The experiments
were replicated in COS-1 cells as well as in a cell line derived
from the human ciliary muscle (hCM) [9] (data not shown).
Initially as a control, we performed a single transfection of
HEK-293T  cells  with  the  cDNAs  encoding  wild-type
myocilin and each of the 5 pathogenic mutations. By western
blot we analyzed the distribution of the mutant proteins in both
the  culture  medium  and  the  cellular  fraction  24  h  after
transfection (Figure 2A). We observed that while 62% of total
wild-type  myocilin  was  present  intracellularly,  more  than
80% of each mutant myocilin accumulated intracellularly.
Interestingly  enough,  small  amounts  of  mutant  myocilins
(ranging from 0.4 to 14.3% of total mutant protein for Q368X
and  D380A  mutations,  respectively)  were  present  in  the
culture  medium,  mainly  as  full-length  molecules  (Figure
2A,B). Next, we studied the effect of wild-type myocilin on
the secretion of mutant myocilins. When the cDNAs encoding
each mutant myocilin were transiently co-transfected with
equal amounts of the cDNA encoding the wild-type protein,
the  presence  of  extracellular  mutant  myocilins  increased
significantly  (Figure  2C,D;  red  bars).  The  percentage  of
missense myocilins in the culture medium ranged from about
7 to 22% for mutants P370L and D380A, respectively. In
contrast, the extracellular level of truncated myocilin Q368X
was very low (<1.5%), even in co-expression with wild-type
myocilin. The fold increase of extracellular full-length mutant
myocilins in heterozygosis ranged from 1.5 to 5.4, for mutants
D380A and E323K, respectively (Figure 2G).
In the same experiments we also analyzed how mutant
myocilins affected secretion of the wild-type protein (Figure
Figure 1. Scheme of wild-type and mutant myocilin cDNA constructs used in this study. The localization of different domains and epitopes
of myocilin is indicated by rectangles filled with different patterns. Numbers correspond to positions in the myocilin amino acid sequence.
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2099Figure 2. Wild-type/mutant myocilin co-expression significantly increases the amount of extracellular mutant myocilin compared to single
mutant expression. HEK-293T cells were transiently transfected with 200 ng of cDNA constructs encoding 5 different myocilin-myc mutants
or wild-type myocilin-myc (A). To model the heterozygous expression of myocilin mutants, cells were co-transfected with 200 ng of cDNAs
encoding each mutant myocilin-myc and 200 ng of a cDNA construct encoding wild-type myocilin-HA. Twenty-four hours after transfection,
the recombinant mutant-myc (C) and wild-type-HA myocilins (E) in both the culture medium and cells were analyzed by 10% polyacrylamide
SDS-PAGE and western blot using either an anti-myc or an anti-HA monoclonal antibody, respectively. Arrows and arrowheads indicate the
position of full-length myocilin (55 kDa), and the 35 kDa processed olfactomedin-containing fragment, respectively. Molecular weight markers
are shown on the left. B, D and F: Densitometric quantitation of full-length myocilin and its processed olfactomedin-containing fragment,
detected in A (bars with oblique lines), C (solid bars), and E (dotted bars). Red bars represent the percentage of extracellular unprocessed
full-length or truncated Q368X myocilin (extracellular myocilin/total myocilin), blue bars correspond to the extracellular olfactomedin-
containing fragment (extracellular 35 kDa myocilin/total myocilin), and yellow bars represent intracellular full-length myocilin or the truncated
Q368X form (intracellular myocilin/total myocilin), respectively. Total myocilin in each experiment was calculated as the sum of all the
myocilin signals in both the culture medium and the cellular fraction. Error bars represent the S.E. of triplicate experiments. To facilitate the
comparison of the percentage of extracellular unprocessed full-length or truncated Q368X myocilin, the corresponding bars form panels B and
D (G) or panel F (H) are represented together. Numbers above bars in panel G indicate the fold-increase of full-length myocilin in
cotransfections versus single transfections. Statistical significance as compared with full-length wild-type myocilin, was calculated using the
Student’s test. The asterisk indicates a p<0.05, the double asterisk indicates a p<0.01 and the triple asterisk indicates a p<0.001.
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21002E,F). The percentage of wild-type myocilin in the culture
medium fell significantly (p<0.05) from 35% (control single
transfection) to about 9-14% when it was co-expressed with
mutants  E323K,  R346T,  or  D380A  (Figure  2H).  The  co-
expression  with  mutants  Q368X  and  P370L  resulted  in  a
remarkable reduction of the extracellular wild-type protein to
approximately 1% (36 fold) and 3.4% (10.5 fold), respectively
(Figure 2H).
The  proportion  of  myc-  and  HA-tagged  wild-type
myocilin in the culture medium and cellular fractions was
similar in single and co-transfections (Figure 2; wild-type
lanes),  indicating  that  co-expression  does  not  affect  the
distribution of the protein. We confirmed that the expression
levels of wild-type and mutant myocilin were similar in co-
transfected  cells  by  western  blot  analysis  using  an  anti-
myocilin  antibody  [33]  that  recognizes  both  types  of
molecules (Figure 3). We did not detect the expression of
endogenous  myocilin  by  western  blot  (Figure  3),  which
allowed  us  to  rule  out  any  significant  interference  of  the
endogenous protein with the different recombinant myocilins
expressed in these cells.
Analysis  of  the  proteolytic  processing  of  myocilin  in
heterozygosis: In the next step of the study we analyzed how
heterozygous  expression  affected  the  processing  of  both
mutant and wild-type myocilin. Transiently transfected cells
were cultured for 96 h to increase the extracellular presence
of the 35 kDa processed fragment of myocilin [15]. In control
single  transfections  40%  of  total  wild-type  myocilin
corresponded to the extracellular processed fragment, 5% to
the extracellular full-length protein, and the remaining 55%
to  the  intracellular  full-length  protein  (Figure  4A,B).  In
contrast, and in accordance with our previous results [9], the
percentage  of  all  extracellular  mutant  COOH-terminal
fragments dropped significantly to values varying from about
0.6% (P370L) to 14.5% (D380A) of total mutant myocilin
(Figure 4A,B; blue bars). As expected the 35 kDa fragment
was not detected in the truncated myocilin Q368X (Figure
4A,B).  In  co-transfections,  all  the  mutant  olfactomedin-
containing  fragments  increased  slightly  (Figure  4C,D),
between 1.3 and 1.8 times compared to single-transfections,
although the differences were not significant (p>0.05) (Figure
4G).
The heterozygous expression of wild-type myocilin with
each of the 5 mutants for 96 h also produced a remarkable drop
in  the  proportion  of  the  extracellular  wild-type  35  kDa
processed fragment (Figure 4E,F; blue bars), from 40% of
Figure 3. Co-expression of wild-type and mutant myocilin does not alter myocilin levels. A: HEK-293T cells were transiently transfected with
200 ng of cDNAs constructs encoding either mutant myocilins E323K or Q368X. These cells were also co-transfected with 200 ng of a cDNA
construct encoding wild-type myocilin-HA and 200 ng of either cDNA encoding mutant myocilin-myc E323K or Q368X. Ninety-six hours
after transfection, total recombinant myocilin in cell lysates were analyzed by 10% polyacrylamide SDS-PAGE and western blot using the
anti-myocilin polyclonal antibody R14T. The black and white arrows indicate the position of full-length myocilin and truncated Q368X
myocilin, respectively. Molecular weight markers are shown on the left. B: densitometric quantitation of myocilin detected in A. Error bars
represent the S.E. of triplicate experiments.
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2101Figure 4. Wild-type/mutant myocilin co-expression reduces significantly the extracellular wild-type olfactomedin cleaved fragment of
myocilin. HEK-293T cells were transiently transfected with 200 ng of cDNA constructs encoding the 5 different myocilin-myc mutants or
wild-type myocilin-myc (A). To model the heterozygous expression of myocilin mutants cells were co-transfected with 200 ng of cDNAs
encoding each mutant myocilin-myc and 200 ng of a cDNA construct encoding wild-type myocilin-HA (C and E). Ninety-six hours after
transfection, recombinant mutant and wild-type myocilins-myc in the culture medium and in cell lysates were analyzed by 10% polyacrylamide
SDS-PAGE and western blot using either an anti-myc or a anti-HA monoclonal antibody, respectively. Arrows and arrowheads indicate the
position of full-length myocilin (55 kDa), and the 35 kDa processed olfactomedin-containing fragment, respectively. Molecular weight markers
are shown on the left. B, D and F: Densitometric quantitation of full-length myocilin and its processed olfactomedin-containing fragment,
detected in A (bars with oblique lines), C (solid bars) and E (dotted bars). Red bars represent the percentage of extracellular full-length or
truncated Q368X myocilin (extracellular myocilin/total myocilin), blue bars correspond to the extracellular olfactomedin-containing fragment
(extracellular 35 kDa myocilin/total myocilin), and yellow bars represent intracellular full-length myocilin or the truncated Q368X form
(intracellular myocilin/total myocilin), respectively. The total myocilin in each experiment was calculated as the sum of all the myocilin signals
in both the culture medium and the cellular fraction. To facilitate the comparison of the percentage of secreted mutant olfactomedin domain
the corresponding bars form panels B and D (G) or panel F (H) are represented together. Error bars represent the S.E. of triplicate experiments.
Statistical significance as compared with the COOH-terminal fragment of wild type myocilin was calculated using the Student’s test. The
triple asterisk indicates a p<0.001.
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2102total  wild-type  myocilin  (control)  to  20%  for  the  D380A
mutant, and to 6%-11% for the other 4 mutants. These values
represent a fold reduction ranging from 2 (D380A) to 6.3
(P370L; Figure 4H). Again, and as expected, the COOH-
terminal myocilin fragment was not present in the truncated
myocilin Q368X (Figure 4C), although the processed COOH-
terminal peptide arising from the wild-type counterpart was
detected with the HA antibody (Figure 4E). Cell viability and
cell lysis at the end of these experiments were determined by
the MTT and LDH assays, respectively. No significant effects
on these two parameters were observed (data not shown).
Aggregation of mutant myocilins co-expressed with wild-type
myocilin: We reasoned that if glaucoma mutations increased
the molecular size of myocilin aggregates, then they could
obstruct  AH  outflow  and  hence  raise  IOP.  Therefore,  we
analyzed  by  nonreducing  SDS-PAGE  and  western  blot
whether  heterozygous  expression  of  myocilin  glaucoma
mutants affected myocilin self-aggregation. Culture media
from cells expressing myocilin for 24 h showed a regular size
pattern of myocilin aggregates, consisting of several bands
larger than 118 kDa (Figure 5A-C; wild-type lanes), where
the lower band probably corresponds to a myocilin dimer.
Aggregates disappeared under reducing conditions (Figure
2A), showing that they are maintained by disulphide bonds in
accordance with previous reports [10,34,35]. Extracellular
myocilin aggregates resulting from transient co-transfection
of HEK-293T cells with equal amounts (200 ng) of cDNA
constructs encoding wild-type and each of the 4 missense
myocilin  mutants  showed  the  same  pattern  and  were
recognized  by  both  anti-HA  and  anti-myc  antibodies,
indicating that they correspond to wild-type/mutant myocilin
heteroaggregates (Figure 5A,B). To facilitate the comparison
of the molecular size of myocilin aggregates, sample volumes
were corrected by normalizing the total amount of myocilin
per  sample  (Figure  5D,E).  In  addition,  the  level  of  the  4
missense mutant myocilins increased in co-expression with
the wild-type protein (Figure 5A versus Figure 5C) agreeing
with the results presented in Figure 2. These data indicate that
mutant/wild-type myocilin heteroaggregation increases the
presence of extracellular mutant myocilin and also show that
glaucoma mutations do not increase the molecular size of
either  myocilin  homo-  or  heteroaggregates  (wild-type/
mutant).  Aggregates  resulting  from  the  co-expression  of
Q368X and wild-type myocilin were only recognized by the
anti-HA antibody, indicating that they are composed of only
the wild-type protein, and suggesting that the olfactomedin
domain  could  be  required  for  correct  formation  of
intermolecular disulphide bonds.
DISCUSSION
Heterozygous  expression  of  myocilin  mutants:  The
mechanism  by  which  heterozygous  glaucoma  mutant
myocilins  cause  either  autosomal  dominant  glaucoma  or
predispose to non-Mendelian POAG is currently not well
understood. Some hypotheses have been proposed over recent
years  in  an  attempt  to  explain  myocilin  glaucoma
pathogenesis. Most of these hypotheses do not consider that
MYOC mutations involved in glaucoma are usually present in
heterozygosis. To gain insight into this issue, we have set up
a cellular model of heterozygous expression of wild-type/
mutant myocilin in HEK-293T cells. Different groups have
consistently  shown  that  pathogenic  mutant  myocilins
transiently  expressed  in  homozygosis  accumulate
intracellularly in cells in culture, probably as a consequence
of protein misfolding [9,18,19,21,24]. Similarly, homozygous
transgenic  mice  expressing  mutant  myocilin  Y423H  [22]
show reduced secretion of myocilin into the AH, although the
animals do not develop glaucoma. Some studies have also
shown that certain myocilin mutants, including E323K and
D380A, are poorly secreted when expressed alone at 37 °C,
and that expressing mutant myocilins at a lower temperature
(30  °C),  a  condition  known  to  facilitate  protein  folding,
enhances their secretion [36]. A few reports have described
that mutant myocilin reduces extracellular wild-type myocilin
[11,19,20]. However, to the best of our knowledge the effect
of wild-type myocilin on mutant myocilin secretion and how
mutant myocilin affects the proteolytic processing of wild-
type myocilin have not been investigated. In accordance with
some of the previous studies, we observed low secretion of
the  5  different  myocilin  mutants  transiently  expressed  in
single  transfection  (homozygosis)  at  37  °C.  Nevertheless,
transient  co-expression  (heterozygosis)  of  each  of  these
mutants with the wild-type protein increased the intracellular
retention of wild-type myocilin and simultaneously raised the
extracellular concentration of mutants (Figure 6; points 1 and
2). Heteroaggregation could explain how mutant and wild
type myocilin affect each other’s secretion. The variations
observed in the extracellular amount of each myocilin mutant
might be due to specific structural defects, which could affect
formation  of  wild-type/mutant  heteroaggregates.  It  is
noteworthy  that  extracellular  missense  mutant  myocilins
represented a significant fraction of the total mutant protein
expressed in this model of heterozygosis, ranging from 8% to
20% for P370L and D380A mutations, respectively (Figure
2C,D). These findings suggest that the AH and extracellular
matrix of the outflow pathway in heterozygous glaucoma
patients  might  contain  significant  amounts  of  mutant
myocilin, higher than previously thought, forming part of
heteroaggregates  (wild-type/mutant).  The  extracellular
mutant myocilin in patients could be secreted by different
tissues such as the ciliary muscle, ciliary epithelium, and TM
cells  [33,37,38].  Therefore,  it  can  be  also  speculated  that
blocking  the  secretion  of  mutant  myocilin  could  be  of
therapeutic value. It is interesting to note that secretion and
processing of myocilin mutations associated with Mendelian
cases of glaucoma did not differed significantly from those
found  in  non-Mendelian  glaucoma,  indicating  that  other
factors should determine the type of inheritance. Our data also
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2103suggest that the amount of wild-type myocilin present in the
AH could be considerably reduced in heterozygosis (between
2.6 and 10.5 times, for the wild-type myocilin co-expressed
with mutants E323K and P370L, respectively). The largest
reduction of extracellular wild-type myocilin was produced
by the nonsense mutation Q368X. In accordance with our
results it has been reported that co-transfection of COS-7 and
TM  cells  with  a  cDNA  encoding  wild-type  myocilin  and
increasing  amounts  of  a  Q368X  cDNA  reduced  the
extracellular wild-type protein [11,19]. Similarly, Joe and co-
workers  [20]  reported  that  wild-type  myocilin-GFP
adenovirally co-expressed in TM cells with 4 missense mutant
myocilins  (G364V,  K423E,  Y437H,  and  I477N)  mainly
accumulated in lysates of human TM cells but was also present
in the culture medium. However, another study did not detect
wild-type  myocilin  in  the  culture  medium  of  TM  cells
adenovirally  co-expressing  wild-type  and  Q368X-GFP
myocilin [39]. This discrepancy could be due to different
experimental conditions and/or to lower detection sensitivity.
Molecular  mechanisms  of  myocilin-associated  glaucoma:
Different  mechanisms  could  contribute  to  the  disease
phenotype in myocilin-associated glaucoma. In accordance
with our results, and as already mentioned, it has been reported
that mutant myocilin inhibits the secretion of the wild-type
protein [11,19,20]. These data suggest that wild-type myocilin
could be absent in the AH of glaucoma patients carrying
MYOC  mutations.  However,  reduction  or  absence  of  the
extracellular normal protein neither explains the apparently
normal  ocular  phenotype  in  both  hemizygous  and
homozygous MYOC-knockout mice [17], nor why mutations
such as K423E, which causes glaucoma in heterozygotes, do
not produce the disease in homozygotes [40]. From our data
we can hypothesize that the presence of extracellular mutant
myocilin could be required to produce the disease phenotype,
Figure 5. Aggregation of wild-type and mutant myocilins co-expressed for 24 h. HEK-293T cells were transiently transfected with cDNA
constructs encoding 5 different myocilin mutants or wild-type myocilin as described in Figure 2. Myocilin aggregates secreted after 24 h of
expression were analyzed by nonreducing SDS-PAGE (4-15% gradient polyacrylamide) and were detected by western blot. The culture media
from co-transfections were analyzed using either an anti-myc antibody to detect mutant myocilin (A), or an anti-HA antibody to detect wild-
type myocilin (B). Control single transfections were analyzed using an anti-myc monoclonal antibody (C). Molecular weight markers are
shown on the right of panels A, B and C. To facilitate the comparison of the molecular size of myocilin aggregates different volumes (1 to 50
μl) of culture medium from panels B (D) and C (E) were loaded into gels and analyzed by nonreducing SDS-PAGE (8% polyacrylamide).
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homozygous  patients.  According  to  this  idea,  it  has  been
reported that this mutation is not secreted when expressed
alone in transiently transfected COS-7 or HTM cells [21],
indicating  that  it  could  be  extracellularly  absent  in
homozygous  subjects.  However,  it  might  be  present
extracellularly  in  heterozygous  patients,  where  it  is  co-
expressed with wild-type myocilin. Likewise, our hypothesis
also explains why mutation T377M, which indeed is detected
extracellularly in single transient transfections of COS-7 or
HTM cells [21], is associated with glaucoma in homozygous
POAG patients [41]. Data obtained from some animal models
of glaucoma support the role of extracellular mutant myocilin
in the pathogenesis of glaucoma. In that sense, it has been
reported that non-secretion of mouse mutant myocilin Y423H,
which  corresponds  to  human  mutation  Y437H,  is  not
sufficient to cause glaucoma in MYOC-knockin transgenic
mice  [22].  However,  the  phenotype  of  transgenic  mouse
expressing the same mouse mutant myocilin [42] or human
myocilin Y437H [23] in the presence of endogenous wild-
type mouse myocilin, show phenotypic features similar to
those of POAG in humans (i.e. moderate elevation of IOP,
loss of approximately 20% of retinal ganglion cells in the
peripheral retina, and axonal degeneration in the optic nerve).
The reasons for the phenotypic differences in these mouse
models are unclear [43].
Interestingly enough, in this study we have also found for
the  first  time  that  the  extracellular  presence  of  mutant
myocilin  is  associated  with  a  reduction  in  the  amount  of
extracellular  processed  wild-type  myocilin  (olfactomedin
domain) by around 2 to 6 times after 96 h in culture. This
phenomenon  (Figure  6;  point  3)  could  also  be  due  to  a
Figure 6. Model of the secretion and proteolytic processing of wild-type/mutant myocilin heteroaggregates. Heteroaggregation takes place in
the lumen of the ER. For simplicity the diagram shows a heterodimer but the aggregates are composed of multiple myocilin monomers
(indicated by dots in the heteroaggregate) linked by disulphide bonds (short black lines in the heterodimer). According to this model
heteroaggregation has three major effects: 1) increases the retention of wild-type myocilin in the ER via a dominant negative effect (DNE);
2) increases secretion of mutant myocilin along with a reduction of extracellular wild-type myocilin, and 3) reduces the amount of extracellular
wild-type myocilin (olfactomedin fragment) under conditions known to increase the proteolytic cleavage of myocilin by calpain II such as 96
h of culture [15]. The N-terminal fragment that arises after the cleavage mainly remains in the ER [15]. A possible gain of function (GOF) of
mutant myocilin (both full-length and cleaved olfactomedin fragment) that could contribute to glaucoma pathogenesis is also indicated. The
leucine zipper (yellow), linker (red), and olfactomedin (blue) domains of myocilin are also indicated in the heterodimer. The ray indicates
mutant myocilin. Question marks indicate a hypothetical dominant negative effect and/or gain of function of the mutant protein.
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and might contribute to the pathogenic mechanism that leads
to IOP rising and glaucoma. Dominant negative effects are
often caused by mutations in multimeric proteins, and imply
that the mutant protein loses its native function and interferes
with that of the wild-type protein. According to our previous
study  [9]  we  found  that  the  four  pathogenic  myocilins
inhibited the proteolytic processing with varying efficiency.
Again we observed that mutation P370L, which produces the
most severe glaucoma phenotype, also elicited the most potent
endoproteolytic cleavage reduction, in both single and double
transfections (Figure 3B,D; blue bars). However, both the
actual  molecular  mechanism  by  which  reduction  of  the
processed myocilin may lead to glaucoma and the physiologic
signal(s)  that  trigger  myocilin  processing  remain  to  be
elucidated.  Our  hypothesis  proposes  that  the  extracellular
presence of mutant myocilin is the primary key factor in
myocilin-associated  glaucoma,  which  as  mentioned
previously,  is  associated  with  the  reduction  of  both
extracellular wild-type myocilin, either as a full-length or
proteolytically  cleaved  protein,  and  mutant  myocilin
processing. One can also speculate that a hypothetical gain of
function of both extracellular heteroaggregates and mutant
olfactomedin-containing  fragments  (Figure  6)  might  alter
myocilin  turnover  and/or  interactions  with  other
macromolecules, leading to myocilin accumulation over time
in the extracellular matrix of tissues of the eye such as the TM
and  the  uveoscleral  outflow  pathway.  Our  results  do  not
support an obstruction of the AH outflow by an increase in the
molecular size of myocilin aggregates. Further studies are
required to determine whether the AH and extracellular matrix
from  glaucoma  patients  carrying  heterozygous  MYOC
mutations contains myocilin heteroaggregates. According to
these  ideas  it  has  also  been  claimed  that  disease-causing
mutations  on  MYOC  likely  act  by  a  gain  of  function
mechanism [17,20], and/or a dominant negative effect [11,
40,44]. Biochemical studies have indicated that the gain of
function might be related to several phenomena including:
intracellular accumulation in the ER of mutant proteins [9,
18,19,32,45], Russell bodies formation and apoptosis [26],
cytotoxicity  induced  by  ER  stress  [20],  reduction  of  its
proteolytic processing [9], exposure of a cryptic signaling site
that  causes  mislocalization  of  the  mutant  protein  to
peroxisomes  [46],  and  abnormal  interaction(s)  between
myocilin and ECM and/or cell surface proteins [21]. Our
hypothesis does not exclude other proposed mechanisms of
myocilin  associated  glaucoma,  instead  it  complement  the
current view of glaucoma pathogenesis.
Regarding the genotype-phenotype relationship, we did
not  find  a  definitive  correlation  between  the  extracellular
levels  of  the  3  missense  myocilins  and  the  phenotype,
indicating  that  other  unknown  factors,  such  a  possible
mutation-specific gain of function, could contribute to the
phenotype.  The  Q368X  myocilin  mutation  represents  a
particular case in glaucoma pathogenesis since it produces a
truncate protein which lacks the COOH-terminal half of the
olfactomedin-like  domain.  Whether  this  difference  could
explain, at least in part, why Q368X is associated with a milder
phenotype and low penetrance remains to be investigated.
In summary, our cellular model of heterozygosis shows
that  co-expression  of  wild-type  and  mutant  myocilins
increases significantly the presence of extracellular mutant
molecules and reduces the amount of either extracellular full-
length or processed wild-type myocilin. These data suggests
that  the  abnormal  protein  could  be  present  through
heteroaggregates in the AH and extracellular matrix of the TM
and uveoscleral AH outflow of glaucoma patients, playing
pivotal roles in the pathogenesis of glaucoma.
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